🚀 VC round data is live in beta, check it out!
MetaVia Valuation Multiples
Discover revenue and EBITDA valuation multiples for MetaVia and similar public comparables like ODI Pharma, BioAtla, Acurx Pharmaceuticals, Gelteq and more.
MetaVia Overview
About MetaVia
MetaVia Inc is a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat cardiometabolic diseases. It has two programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and obesity. DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and Type 2 Diabetes Mellitus (T2DM). DA-1726 is a novel oxyntomodulin (OXM) analogue functioning as a GLP-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist for the treatment of obesity that is designed to be administered once weekly subcutaneously.
Founded
2014
HQ
Employees
9
Website
Sectors
Financials (LTM)
Market Cap
$7M
MetaVia Financials
MetaVia reported last 12-month revenue of —.
In the same LTM period, MetaVia generated — in gross profit and had net loss of ($14M).
Revenue (LTM)
MetaVia P&L
In the most recent fiscal year, MetaVia reported revenue of — and EBITDA of ($14M).
MetaVia expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | — | XXX | ($14M) | XXX | XXX | XXX |
| Net Profit | ($14M) | XXX | ($13M) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
MetaVia Stock Performance
MetaVia has current market cap of $7M.
Market Cap Evolution
MetaVia's stock price is $1.41.
| Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|
| $7M | 0.0% | XXX | XXX | XXX | $-2.55 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialMetaVia Valuation Multiples
MetaVia trades at 0.2x EV/EBITDA.
EV / Revenue (LTM)
MetaVia Financial Valuation Multiples
As of April 12, 2026, MetaVia has market cap of $7M.
Equity research analysts estimate MetaVia's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
MetaVia has a P/E ratio of (0.5x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $7M | XXX | $7M | XXX | XXX | XXX |
| EV (current) | ($3M) | XXX | ($3M) | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 0.2x | XXX | XXX | XXX |
| EV/EBIT | 0.2x | XXX | 0.2x | XXX | XXX | XXX |
| P/E | (0.5x) | XXX | (0.6x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | 0.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified MetaVia Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
MetaVia Margins & Growth Rates
MetaVia's revenue in the last fiscal year grew by —.
MetaVia's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $1.5M for the same period.
MetaVia Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | — | XXX | (52%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $1.5M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
MetaVia Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| ODI Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| BioAtla | XXX | XXX | XXX | XXX | XXX | XXX |
| Acurx Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Gelteq | XXX | XXX | XXX | XXX | XXX | XXX |
| Chosa Oncology | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
MetaVia M&A Activity
MetaVia acquired XXX companies to date.
Last acquisition by MetaVia was on XXXXXXXX, XXXXX. MetaVia acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by MetaVia
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialMetaVia Investment Activity
MetaVia invested in XXX companies to date.
MetaVia made its latest investment on XXXXXXXX, XXXXX. MetaVia invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by MetaVia
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout MetaVia
| When was MetaVia founded? | MetaVia was founded in 2014. |
| Where is MetaVia headquartered? | MetaVia is headquartered in United States. |
| How many employees does MetaVia have? | As of today, MetaVia has over 9 employees. |
| Who is the CEO of MetaVia? | MetaVia's CEO is Hyung Heon Kim. |
| Is MetaVia publicly listed? | Yes, MetaVia is a public company listed on Nasdaq. |
| What is the stock symbol of MetaVia? | MetaVia trades under MTVA ticker. |
| When did MetaVia go public? | MetaVia went public in 2016. |
| Who are competitors of MetaVia? | MetaVia main competitors are ODI Pharma, BioAtla, Acurx Pharmaceuticals, Gelteq. |
| What is the current market cap of MetaVia? | MetaVia's current market cap is $7M. |
| Is MetaVia profitable? | No, MetaVia is not profitable. |
| What is the current net income of MetaVia? | MetaVia's last 12 months net income is ($14M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.